Samsung Biologics acquires GlaxoSmithKline's US plant for 280 million dollars
Golden Longhui April 1｜Samsung Biologics, a subsidiary of the Samsung Group, announced on Wednesday that it has spent $280 million to acquire a factory in the United States from the British pharmaceutical giant GSK. Samsung Biologics stated that the factory, located in Rockville, Maryland, has a production capacity of 60,000 liters of active pharmaceutical ingredients, bringing the company's total production capacity to 845,000 liters.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Eurozone Q3 GDP rises faster by 0.6% vs. flash estimates of 0.4%
Silver price today: Silver broadly unchanged, according to FXStreet data
Strategy CEO Phong Le says MSCI exclusion has little impact, about 3% of stocks are related to the index
Crypto prices
More
